Redx Pharma Ltd
R&D/Manufacturing
- Website
- https://www.redxpharma.com/
- Membership category
- Corporate
Block 33, Mereside, Macclesfield, SK10 4TG, United Kingdom
Redx Pharma Ltd at a glance
About Redx Pharma Ltd
Our core strengths in medicinal chemistry and translational science have enabled us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is an opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered six molecules to clinical stage development.
Our strategic focus is on advancing our differentiated lead asset, RXC008, a potential first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease and building our programme targeting DDR, a novel fibrosis target. We have earmarked key programmes in our pipeline for partnership including zelasudil (RXC007), a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and multiple fibrotic diseases and zamaporvint (RXC004), a clinical stage Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy.
